Radnor Capital Management LLC purchased a new stake in shares of Maximus, Inc. (NYSE:MMS - Free Report) in the third quarter, according to the company in its most recent filing with the SEC. The firm purchased 21,675 shares of the health services provider's stock, valued at approximately $2,019,000.
A number of other large investors have also recently modified their holdings of the business. V Square Quantitative Management LLC purchased a new position in Maximus in the 3rd quarter worth approximately $25,000. GAMMA Investing LLC increased its stake in Maximus by 224.5% in the 2nd quarter. GAMMA Investing LLC now owns 344 shares of the health services provider's stock worth $29,000 after purchasing an additional 238 shares during the period. Blue Trust Inc. increased its stake in Maximus by 201.5% in the 2nd quarter. Blue Trust Inc. now owns 392 shares of the health services provider's stock worth $33,000 after purchasing an additional 262 shares during the period. Archer Investment Corp increased its stake in Maximus by 8,788.9% in the 2nd quarter. Archer Investment Corp now owns 800 shares of the health services provider's stock worth $69,000 after purchasing an additional 791 shares during the period. Finally, Ariadne Wealth Management LP purchased a new position in Maximus in the 2nd quarter worth approximately $90,000. Institutional investors own 97.21% of the company's stock.
Maximus Trading Up 1.2 %
Shares of MMS traded up $1.10 during mid-day trading on Wednesday, hitting $89.53. 1,325,881 shares of the company's stock traded hands, compared to its average volume of 348,290. The company has a quick ratio of 1.59, a current ratio of 1.59 and a debt-to-equity ratio of 0.61. Maximus, Inc. has a 1 year low of $75.22 and a 1 year high of $93.97. The firm has a market capitalization of $5.39 billion, a P/E ratio of 18.77 and a beta of 0.77. The business's 50-day moving average price is $89.52 and its 200-day moving average price is $87.83.
Maximus (NYSE:MMS - Get Free Report) last posted its earnings results on Wednesday, August 7th. The health services provider reported $1.74 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.47 by $0.27. Maximus had a return on equity of 20.91% and a net margin of 5.59%. The firm had revenue of $1.31 billion for the quarter, compared to analysts' expectations of $1.29 billion. During the same period in the previous year, the firm earned $0.78 earnings per share. The business's revenue was up 10.6% compared to the same quarter last year. As a group, sell-side analysts forecast that Maximus, Inc. will post 6.12 EPS for the current fiscal year.
Maximus Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Saturday, November 30th. Stockholders of record on Friday, November 15th will be paid a dividend of $0.30 per share. The ex-dividend date is Friday, November 15th. This represents a $1.20 annualized dividend and a dividend yield of 1.34%. Maximus's dividend payout ratio (DPR) is presently 25.16%.
Insider Activity
In other news, insider Michelle F. Link sold 1,363 shares of the business's stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $92.56, for a total transaction of $126,159.28. Following the transaction, the insider now directly owns 6,567 shares of the company's stock, valued at approximately $607,841.52. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.40% of the company's stock.
Maximus Profile
(
Free Report)
Maximus, Inc operates as a provider of government services in the United States and internationally. It operates through three segments: U.S. Federal Services, U.S. Services, and Outside the U.S. The U.S. Services segment offers program eligibility support and enrollment; centralized multilingual customer contact centers, multichannel, and digital self-service options for enrollment; application assistance and independent health plan choice counseling; beneficiary outreach, education, eligibility, enrollment, and redeterminations; and person-centered independent disability, long-term sick, and other health assessments.
Featured Articles
Before you consider Maximus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maximus wasn't on the list.
While Maximus currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.